3 Growth Stocks With Insider Ownership Up To 14%

In This Article:

In the midst of a global market recovery, U.S. stocks have shown solid gains, particularly in the technology sector, bolstering hopes for a "soft landing" for the economy. As growth stocks continue to outpace value shares, it's crucial to identify companies with strong insider ownership as this often signals confidence from those closest to the business. When evaluating growth stocks in today's market environment, high insider ownership can be an important indicator of potential success and alignment between company leadership and shareholders.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)

11.9%

21.2%

Atlas Energy Solutions (NYSE:AESI)

29.1%

42.6%

Kirloskar Pneumatic (BSE:505283)

30.6%

30.1%

Medley (TSE:4480)

34%

30.5%

On Holding (NYSE:ONON)

28.4%

24.7%

Clinuvel Pharmaceuticals (ASX:CUV)

13.6%

27%

Credo Technology Group Holding (NasdaqGS:CRDO)

14.4%

60.9%

Adveritas (ASX:AV1)

21.1%

103.9%

Plenti Group (ASX:PLT)

12.8%

106.4%

EHang Holdings (NasdaqGM:EH)

32.8%

74.9%

Click here to see the full list of 1489 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Pharma Mar

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various regions including Europe and the United States, with a market cap of €673.49 million.

Operations: The company's revenue from oncology amounts to €194.09 million.

Insider Ownership: 11.9%

Pharma Mar, S.A. shows potential as a growth company with high insider ownership. Despite a slight decline in sales to EUR 42.02 million for H1 2024, its revenue increased to EUR 80.84 million. Net income dropped to EUR 3.54 million, but the company is forecasted to grow earnings by 53.33% annually and achieve profitability within three years, outpacing the Spanish market's revenue growth rate of 4.7%. Recent positive trial data for Zepzelca® further supports its innovative therapeutic pipeline in oncology.

BME:PHM Ownership Breakdown as at Aug 2024
BME:PHM Ownership Breakdown as at Aug 2024

Norbit

Simply Wall St Growth Rating: ★★★★★☆

Overview: Norbit ASA provides technology products and solutions with a market cap of NOK 5.71 billion.

Operations: Norbit ASA's revenue segments are as follows: null.

Insider Ownership: 14.6%